Evaluation of restrictive left ventricular physiology on echocardiography in heart transplant recipients and early angiographic cardiac allograft vasculopathy Authors: Roscoe Lim, Lebei Pi, Abigal McDonald, Harun Abdullah, Victor Leal Alcantara, Yasbanoo Moayedi, Juan Duero Posada, Ana Carolina Alba, Michael McDonald, Filio Billia, Natasha Aleksova Published: 2026 ABSTRACT This retrospective observational study aimed to determine whether echocardiographic markers of restrictive physiology can identify early cardiac allograft vasculopathy (CAV). There were 136 heart transplant (HT) recipients evaluated between January 2018 and December 2023. The echocardiographic parameters assessed were E/A ratio, isovolumetric relaxation time (IVRT), deceleration time (DT), E/e’, and tissue Doppler indices. The primary outcome was angiographic CAV (ISHLT grade ≥1) at 1 year, which was observed in 15% of recipients. Only DT <150 ms was significantly associated with CAV (OR 2.73, 95% CI 1.03–7.21). A multivariable model incorporating age, sex, and DT <150 ms demonstrated good discrimination for CAV (AUC 0.78). These findings suggest that DT may be a non-invasive marker of early CAV and merit further studies to determine long-term risk prediction. Background Cardiac allograft vasculopathy (CAV) develops early after HT and is a major cause of morbidity and mortality later in the transplant course.1 The International Society for Heart and Lung Transplantation (ISHLT) classified CAV from grade 0–3. CAV0 indicates no detectable angiographic lesions. Mild CAV (CAV1) involves limited coronary narrowing (left main <50%, primary vessel <70%, or branch <70%) without allograft dysfunction. Moderate CAV (CAV2) includes more significant diseases (≥70% stenosis in a single primary vessel or in branches of two systems) without graft dysfunction. Severe CAV (CAV3) refers to extensive disease (left main ≥50%, ≥70% stenosis in two or more primary vessels, or branches in all three systems) with the presence of allograft dysfunction or restrictive physiology in patients with CAV1 or CAV2. Data from a single study that defined restriction as echocardiographic E to A velocity ratio (E/A) >2, shortened isovolumetric relaxation time (IVRT) <60 msec, shortened deceleration time (DT) ≤150 msec, or restrictive hemodynamic values (right atrial pressure >12 mmHg, pulmonary capillary wedge pressure >25 mmHg, cardiac index <2.0 l/min/m2) was used to inform the ISHLT CAV definition.2 However echocardiographic criteria for the evaluation of restrictive physiology in the setting of CAV have not been well studied in the HT population. Therefore, our study aimed to determine if echocardiographic criteria for restrictive physiology, performed within 3 months of invasive coronary angiography (ICA), can identify angiographic CAV at 1 year in a contemporary cohort. Methods We conducted a retrospective observational study of consecutive adult HT recipients between Jan 2018-Dec 2023 at Toronto General Hospital. Multi-organ and heart–retransplant recipients were excluded. Echocardiographic criteria for restrictive physiology were defined as E/A >2, IVRT <60 msec, and DT ≤150 msec as defined by ISHLT.3 We also evaluated E/e’ and tissue doppler parameters. The primary outcome was ISHLT CAV grade 1–3 identified on ICA 1 year after HT. The echocardiogram and ICA had to be completed within 3 months of each other. Logistic regression was used to evaluate the association between the echocardiographic parameters and CAV at 1-year post-transplant. Sensitivity and specificity were calculated however the main focus of this work was to evaluate the risk association rather than test performance between echo parameters and CAV. AUC analysis was conducted using StataCorp 2025, College Station, TX. Results We identified 136 HT recipients, most of whom were male (71%) with a median age of 52 years (IQR 37–60). Non-ischemic cardiomyopathy (66%) was the most common indication for HT. Most received anti-thymocyte globulin (96%) for induction. 36 recipients (27%) required an LVAD as a bridge to transplant. At 1 year, 21 (15%) recipients had developed ISHLT CAV 1–3 (Table 1). The median time between the echocardiograms and ICA was 39 days (IQR 16 – 71).Table 1Baseline CharacteristicsCharacteristicTotal Cohort (n = 136)ISHLT CAV Grade 1–3 (n= 21)ISHLT CAV Grade 0 (n = 115)p-valueAge at Transplant, median years (IQR)52 (37−60)59 (49−63)51(35−60)0.07Female, n (%)40 (29)2 (10)38 (33)0.03BMI, median (IQR)26 (23−30)26 (24−28)26 (23−30)0.39Donor age (IQR)34.5 (24−42)38 (31−43)32 (24−42)0.09Comorbidities, n (%)Hypertension38 (28)5 (24)33 (29)0.65Dyslipidaemia43 (32)6 (29)37 (32)0.74Diabetes29 (21)5 (24)24 (21)0.76Chronic kidney disease34 (25)7 (33)27 (24)0.39Heart failure etiology, n (%)Ischemic28 (21)6 (29)22 (19)0.32Non-ischemic90 (66)15 (71)75.0 (65.2)0.58Congenital18 (13)0 (0)18 (16)0.80LVAD, n (%)36 (27)6 (29)30 (26)0.79Induction, n (%)ATG130 (96)21 (100)109 (95)0.59*Basiliximab6 (4)0 (0)6 (5)Ischemic time, median in minutes (IQR)194 (147−235)156 (132−201)201 (150−243)0.08Rejection in the first yearAntibody-mediated ≥ 16 (4)0 (0)6 (5)0.65*Cellular-mediated ≥ 2R65 (48)9 (43)56 (41)0.79*Fisher’s exact p-value. Table 1Baseline CharacteristicsCharacteristicTotal Cohort (n = 136)ISHLT CAV Grade 1–3 (n= 21)ISHLT CAV Grade 0 (n = 115)p-valueAge at Transplant, median years (IQR)52 (37−60)59 (49−63)51(35−60)0.07Female, n (%)40 (29)2 (10)38 (33)0.03BMI, median (IQR)26 (23−30)26 (24−28)26 (23−30)0.39Donor age (IQR)34.5 (24−42)38 (31−43)32 (24−42)0.09Comorbidities, n (%)Hypertension38 (28)5 (24)33 (29)0.65Dyslipidaemia43 (32)6 (29)37 (32)0.74Diabetes29 (21)5 (24)24 (21)0.76Chronic kidney disease34 (25)7 (33)27 (24)0.39Heart failure etiology, n (%)Ischemic28 (21)6 (29)22 (19)0.32Non-ischemic90 (66)15 (71)75.0 (65.2)0.58Congenital18 (13)0 (0)18 (16)0.80LVAD, n (%)36 (27)6 (29)30 (26)0.79Induction, n (%)ATG130 (96)21 (100)109 (95)0.59*Basiliximab6 (4)0 (0)6 (5)Ischemic time, median in minutes (IQR)194 (147−235)156 (132−201)201 (150−243)0.08Rejection in the first yearAntibody-mediated ≥ 16 (4)0 (0)6 (5)0.65*Cellular-mediated ≥ 2R65 (48)9 (43)56 (41)0.79*Fisher’s exact p-value. Baseline Characteristics *Fisher’s exact p-value. DT < 150 ms at 1 year was significantly associated with presence of angiographic CAV at 1 year (OR 2.73, 95% CI 1.03–7.21, p=0.04). Conversely, E/A (OR 0.88, 95% CI 0.32–2.45, p=0.81) and IVRT (OR 0.75, 95% CI 0.23–2.44, p=0.63) were not associated with angiographic CAV. A model including age, sex and DT <150 ms on 1 year echocardiogram had good discrimination for CAV at 1 year (AUC is 0.78, p=0.018, Figure 1). Donor age and rejection were not associated with DT < 150 ms (p=0.13 and p=0.36 respectively) and neither variable improved model performance (AUC of 0.74 and 0.73 respectively). Other parameters of restrictive physiology including E/e’ > 14, septal e’, and lateral e’ were not associated with angiographic CAV (Table 2).Figure 1AUC analysis of echocardiographic restrictive physiology parameters at 1 year and angiographic CAV at 1 year.Table 2Echocardiographic restrictive parameters in comparison to coronary allograph vasculopathyECHO ParametersTotal Cohort (n = 136)ISHLT CAV Grade 1–3 (n= 21)ISHLT CAV Grade 0 (n = 115)p-valueLV Ejection Fraction, mean (%)60.1±5.659.7±5.960.2±5.60.37Mitral E-wave velocity, mean (m/s)0.9±0.20.8±0.20.9±0.20.14Mitral A-wave velocity, mean0.4±0.20.4±0.10.4±0.20.51Mitral E/A ratio, mean2.3±0.82.3±0.92.3±0.80.93Septal e′ velocity, mean9.0±2.39.0±2.39.0±2.30.95Lateral e′ velocity, mean11.9±3.011.5±3.212.0±3.00.48E/e′ ratio, mean8.6±2.98.5±3.28.6±2.90.39Isovolumetric relaxation time, mean (ms)79.0±25.884.4±30.077.7±24.60.16Deceleration time, mean (ms)172.2±44.5183.9±45.9169.5±43.90.20RAP estimate, mean (mmHg)4.0±2.74.3±2.94.0±2.70.32 AUC analysis of echocardiographic restrictive physiology parameters at 1 year and angiographic CAV at 1 year. Table 2Echocardiographic restrictive parameters in comparison to coronary allograph vasculopathyECHO ParametersTotal Cohort (n = 136)ISHLT CAV Grade 1–3 (n= 21)ISHLT CAV Grade 0 (n = 115)p-valueLV Ejection Fraction, mean (%)60.1±5.659.7±5.960.2±5.60.37Mitral E-wave velocity, mean (m/s)0.9±0.20.8±0.20.9±0.20.14Mitral A-wave velocity, mean0.4±0.20.4±0.10.4±0.20.51Mitral E/A ratio, mean2.3±0.82.3±0.92.3±0.80.93Septal e′ velocity, mean9.0±2.39.0±2.39.0±2.30.95Lateral e′ velocity, mean11.9±3.011.5±3.212.0±3.00.48E/e′ ratio, mean8.6±2.98.5±3.28.6±2.90.39Isovolumetric relaxation time, mean (ms)79.0±25.884.4±30.077.7±24.60.16Deceleration time, mean (ms)172.2±44.5183.9±45.9169.5±43.90.20RAP estimate, mean (mmHg)4.0±2.74.3±2.94.0±2.70.32 Echocardiographic restrictive parameters in comparison to coronary allograph vasculopathy As a secondary analysis, DT < 150 ms had a sensitivity of 50% (95% CI: 27–83%) and specificity of 73% (95% CI: 64–81%) for angiographic CAV, corresponding to a positive likelihood ratio of 1.87 (95% CI 1.09 – 3.19) and a negative likelihood ratio of 0.68 (95% CI: 0.43 – 1.07). Discussion ISHLT recommends routine ICA for CAV surveillance in HT recipients.3 However, ICA is invasive, resource-intensive, and limited in patients with renal dysfunction. Therefore, non-invasive echocardiographic parameters may offer a complementary approach to identifying recipients at higher CAV risk and enable individualized risk-based strategies for CAV surveillance. The ISHLT definition of severe CAV incorporates restrictive echocardiographic physiology as a marker of advanced allograft dysfunction.3 In this cohort, DT <150 ms on the echocardiogram was associated with an odds ratio of 2.73 for angiographic CAV at 1 year, however other echocardiographic parameters of restrictive physiology were not. DT reflects left ventricular (LV) compliance and the rate of pressure equalization between the left atrium and LV during early diastole.4, 5 In a stiff, noncompliant LV, rapid early inflow is followed by abrupt deceleration as LV diastolic pressure rises, resulting in a shortened DT.4 As such, DT provides a relatively direct assessment of passive LV stiffness and early diastolic pressure–volume relationships, which are central features of restrictive physiology. This may also suggest that DT reflects early passive stiffness that precede overt restrictive filling pattern. E/A ratio is highly load-dependent parameter reflecting the balance between early passive filling and late atrial contraction.5 While extreme values may suggest restrictive filling, the E/A ratio is prone to pseudonormalization as filling pressures rise, masking worsening LV compliance.4 The E/A ratio is highly sensitive to atrial function, preload, and heart rate. In the transplant setting, altered atrial anatomy, impaired atrial contractility, and denervation could further limit its discriminatory value. IVRT reflects active myocardial relaxation rather than passive relaxation and is strongly influenced by heart rate and autonomic tone.4, 5 In HT recipients where there is denervation leading to elevated baseline heart rates and altered atrial anatomy, IVRT and E/A ratio become confounded and unreliable. Tissue doppler velocities assess relaxation velocity rather than LV stiffness which may remain relatively normal in early restrictive physiology.4 The lack of association between E/A, IVRT, or tissue doppler velocities with CAV may reflect a unique post-transplant physiology that results from atrial anastomotic changes and denervation. In addition to the implications of a small, single-centre study with a modest CAV rate, several additional limitations merit consideration. ISHLT echocardiographic criteria for restrictive physiology may be confounded by post-transplant atrial changes, denervation, surgical manipulation of the left atrium, variability in pulmonary venous flow and donor–recipient size mismatch notably over- and undersizing.3, 5 Residual confounding is possible as restrictive filling patterns can be influenced by factors such as heart rate, elevated filling pressures, rejection episodes, or donor–recipient characteristics and should be incorporated in future studies. Selection bias may also be present by limiting analysis to patients who survived and underwent both echocardiography and angiography at 1 year. Although DT <150 ms was associated with CAV, the wide 95% confidence interval (1.03–7.21) reflects limited event numbers and sample size. The modest specificity also reflects that a DT <150 ms is unlikely to serve as a standalone diagnostic test however the strength of the association of this readily available echocardiographic finding with angiographic CAV early after HT is of merit and warrants further study. Echocardiography is an easily accessible and noninvasive investigation that provides reproducible parameters that could complement ICA in identifying patients at higher risk of early CAV. If validated in larger, multicenter cohorts, DT may help risk stratify and inform the intensity of surveillance of immunomodulatory strategies. Further studies may also clarify its relationship with CAV severity, progression, and long-term outcomes after HT. Funding sources There are no funding sources for this project. Disclosure statement The authors have no relevant relationships to the content of this paper to disclose. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.